📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Jagsonpal Pharma Approves ₹40 Cr Buyback at ₹250 Per Share via Tender Offer
Jagsonpal Pharmaceuticals has approved a buyback of up to 16 lakh equity shares, representing 2.39% of its total paid-up equity capital. The buyback is priced at ₹250 per share, involving a total outlay of ₹40 crore, which constitutes 18.35% of the company's net worth as of March 2025. The process will be conducted via the tender offer route, allowing existing shareholders to participate on a proportionate basis. Notably, the promoter group has decided not to participate, which will result in their stake increasing from 67.2% to approximately 68.9% post-buyback.
Key Highlights
Buyback of up to 16,00,000 equity shares at a fixed price of ₹250 per share
Total buyback size of ₹40 crore represents 18.35% of paid-up capital and free reserves
The offer is conducted through the tender offer route on a proportionate basis
Promoters will not participate, leading to an indicative stake increase from 67.2% to 68.9%
Centrum Capital Limited has been appointed as the Manager to the Buyback
💼 Action for Investors
Investors should compare the ₹250 offer price with the current market price to evaluate potential arbitrage or exit opportunities. The non-participation of promoters is a positive signal and may lead to a higher acceptance ratio for retail shareholders.
Jagsonpal Pharma Board Approves ₹40 Crore Buyback at ₹250 Per Share via Tender Route
Jagsonpal Pharmaceuticals has announced a buyback of 16 lakh shares, representing 2.39% of its total paid-up equity capital. The buyback is priced at ₹250 per share, involving a total cash outlay of ₹40 crore, which is 18.35% of the company's net worth. The process will be conducted through the tender offer route, allowing shareholders to participate on a proportionate basis. Notably, the promoters have opted not to participate, which will result in their stake increasing from 67.2% to approximately 68.9% post-completion.
Key Highlights
Buyback of up to 16,00,000 equity shares at a fixed price of ₹250 per share
Total offer size of ₹40 crore represents 18.35% of paid-up capital and free reserves
Buyback to be executed via the tender offer route on a proportionate basis
Promoters and Promoter Group will not participate in the buyback offer
Centrum Capital Limited appointed as the Manager to the Buyback
💼 Action for Investors
Investors should evaluate the buyback price of ₹250 against the current market price for potential arbitrage or exit opportunities. Since promoters are not participating, the acceptance ratio for retail shareholders is likely to be higher.
Jagsonpal Pharma Q3 PAT Rises 10% to ₹12.5 Cr; Management Guides for Q4 Recovery
Jagsonpal Pharmaceuticals reported a flattish Q3 FY26 with revenue at ₹73 crores, though PAT grew 10% YoY to ₹12.5 crores. The company faced headwinds as its relevant market (RPM) grew only 3-3.5% compared to the broader pharma market's 8% growth. Management attributed the performance to internal recalibrations and leadership transitions, including a ₹2.1 crore one-time provision for the new labor code. Despite the slow quarter, the company maintains a strong cash position of ₹176 crores and expects double-digit growth to resume from Q4 FY26.
Key Highlights
Q3 FY26 Revenue stood at ₹73 crores, while 9M FY26 revenue grew 6% YoY to ₹223 crores.
PAT for the quarter increased by 10% YoY to ₹12.5 crores with margins improving 180 bps to 17.1%.
Free cash balance reached ₹176 crores, reflecting an increase of ₹15.2 crores during the quarter.
Exceptional item of ₹2.1 crores provided for past service costs related to the new labor code.
Management expects growth acceleration to double digits starting from Q4 FY26 following field force recalibration.
💼 Action for Investors
Investors should monitor the promised recovery in Q4 to see if internal leadership changes and strategy refreshes translate into higher volume growth. The strong cash position and debt-free status provide a significant cushion for future expansion or acquisitions.
Jagsonpal Pharma Q3 PAT Rises 10% to ₹125 Mn; 9M PAT Up 12.5% with Strong Cash Reserves
Jagsonpal Pharmaceuticals reported a steady performance for 9MFY26 with Operating PAT growing 12.5% YoY to ₹359 million. While Q3 revenue was largely flat at ₹729 million, the company achieved significant margin expansion, with Operating PAT margins rising 160 bps to 17.1%. A key highlight is the robust cash balance of ₹1,757 million, which increased by ₹152 million during the quarter. Management has expressed confidence in stronger growth starting from Q4 FY26, backed by new product launches and focused initiatives.
Key Highlights
9MFY26 Operating PAT grew 12.5% YoY to ₹359 Mn with margins expanding 95 bps to 16.1%.
Q3FY26 Operating PAT increased 10% YoY to ₹125 Mn despite a marginal 1% dip in revenue to ₹729 Mn.
Cash and equivalents reached ₹1,757 Mn as of Dec 31, 2025, providing significant liquidity for inorganic growth.
Operating EBITDA (pre-ESOP) for 9MFY26 stood at ₹503 Mn, reflecting a 5% YoY increase.
The company provided ₹21 Mn in Q3 for potential past service costs related to the new labour code.
💼 Action for Investors
Investors should monitor the company's ability to translate its high cash reserves into inorganic growth through brand or business acquisitions. The stock remains attractive due to its asset-light model and margin expansion, but the promised growth acceleration in Q4 will be a key performance indicator.
Jagsonpal Pharma Q3 PAT Rises 10% to ₹125 Mn; 9M PAT Up 12.5% with Strong Cash Position
Jagsonpal Pharmaceuticals reported a 12.5% YoY increase in Operating PAT for 9MFY26, reaching ₹359 million, despite a modest 6% revenue growth. For the Q3FY26 quarter, revenue was slightly down by 1% at ₹729 million, but Operating PAT grew by 10% to ₹125 million as margins expanded to 17.1%. The company maintains a very strong liquidity position with a cash balance of ₹1,757 million, increasing by ₹152 million during the quarter. Management remains optimistic about stronger growth starting from Q4 FY26.
Key Highlights
9MFY26 Operating PAT grew 12.5% YoY to ₹359 Mn with margins expanding 95 bps to 16.1%
Q3FY26 Revenue remained flat at ₹729 Mn, while Operating PAT rose 10% to ₹125 Mn
Cash and equivalents reached ₹1,757 Mn as of Dec 31, 2025, providing significant inorganic growth potential
Operating EBITDA margins remained resilient at 22.7% for Q3 and 22.6% for the nine-month period
Company provided ₹21 Mn for additional past service costs related to the new labor code
💼 Action for Investors
Investors should focus on the company's ability to maintain high margins and its massive cash pile for potential M&A. Monitor Q4 results to see if the promised growth acceleration materializes.
Jagsonpal Pharma Q3 Operating PAT up 10% to ₹125 Mn; Cash Reserves Reach ₹1,757 Mn
Jagsonpal Pharmaceuticals reported a 12.5% YoY growth in 9MFY26 Operating PAT to ₹359 million, driven by operational discipline and a 6% revenue increase. For Q3FY26, while revenue was flat at ₹729 million, Operating PAT rose 10% YoY to ₹125 million with margins expanding to 17.1%. The company's cash balance strengthened significantly to ₹1,757 million, providing a solid foundation for future inorganic growth. Management has signaled a more aggressive growth trajectory starting from Q4 FY26.
Key Highlights
9MFY26 Operating PAT rose 12.5% YoY to ₹359 Mn; Operating PAT margins expanded by 95 bps to 16.1%
Q3FY26 Revenue remained stable at ₹729 Mn, while Operating PAT increased 10% YoY to ₹125 Mn
Cash and equivalents increased by ₹152 Mn during the quarter to reach a total of ₹1,757 Mn
Operating EBITDA (pre-ESOP) for 9MFY26 grew 5% YoY to ₹503 Mn with a 22.6% margin
A provision of ₹21 Mn was made in Q3 for past service costs related to the new labor code
💼 Action for Investors
Investors should monitor the promised growth acceleration in Q4 FY26 and potential inorganic acquisitions using the company's significant cash reserves. The stock remains a steady play on domestic chronic and sub-chronic pharma segments with improving profitability.
Jagsonpal Pharma Q3 Net Profit Falls 17.8% YoY to ₹10.98 Cr; Revenue Flat at ₹72.9 Cr
Jagsonpal Pharmaceuticals reported a marginal YoY revenue decline to ₹729.45 million for the quarter ended December 31, 2025. Net profit dropped significantly by 17.8% YoY to ₹109.78 million, primarily weighed down by a ₹20.79 million exceptional charge related to new labor code transitions. While 9-month revenue showed a 6.1% growth to ₹2,230.22 million, overall profitability for the period is lower than the previous year. The company is also dealing with a ₹15.20 million GST demand, which it intends to appeal.
Key Highlights
Q3 Revenue from operations stood at ₹729.45 million vs ₹740.25 million in the previous year's quarter.
Net Profit for Q3 declined to ₹109.78 million from ₹133.57 million YoY.
Exceptional expense of ₹20.79 million recognized due to the enactment of New Labour Codes affecting employee benefits.
9-month revenue grew 6.1% YoY to ₹2,230.22 million, though 9-month profit fell to ₹320.53 million from ₹345.74 million.
Company is contesting a ₹15.20 million GST demand from the Haryana SGST office regarding ITC mismatches.
💼 Action for Investors
The decline in both quarterly revenue and profit suggests a challenging operating environment; investors should wait for signs of margin recovery. Monitor the integration of the Yash Pharma business and the resolution of the GST demand for future impact.